COVID-19: What Are the Symptoms? COVID-19 is a new respiratory illness that has been causing concern around the world. It is caused by a virus called SARS-CoV-2, which is a member of the Coronavirus family. Symptoms of COVID-19 can range from mild to severe and can include fever, cough, shortness of breath, and difficulty breathing. It is important to note that not everyone who is infected with the virus will experience symptoms. If you have recently been in an area with a known outbreak of COVID-19, you should monitor your health for any of these symptoms and seek medical attention if you experience any. It is important to remember to practice social distancing and good hygiene to help prevent the spread of the virus.
Acute symptomatic epileptic seizures are frequently seen in neurocritical care. To prevent subsequent unprovoked seizures, long-term treatments with antiseizure medications are often initiated although supporting evidence is lacking. This study aimed at prospectively assessing the risk of unprovoked seizure relapse with respect to the use of antiseizure medications. It was hypothesized that after a first acute symptomatic seizure of structural etiology, the cumulative 12-month risk of unprovoked seizure relapse is ≤ 25%. Inclusion criteria were age ≥ 18 and acute symptomatic first-ever epileptic seizure; patients with status epilepticus were excluded. Using telephone and mail interviews, participants were followed for 12 months after the acute symptomatic first seizure. Primary endpoint was the occurrence and timing of a first unprovoked seizure relapse. In addition, neuro-intensivists in Germany were interviewed about their antiseizure treatment strategies through an anonymous online survey. Eleven of 122 participants with structural etiology had an unprovoked seizure relapse, resulting in a cumulative 12-month risk of 10.7% (95%CI, 4.7%–16.7%). None of 19 participants with a non-structural etiology had a subsequent unprovoked seizure. Compared to structural etiology alone, combined infectious and structural etiology was independently associated with unprovoked seizure relapse (OR 11.1; 95%CI, 1.8–69.7). Median duration of antiseizure treatment was 3.4 months (IQR 0–9.3). Seven out of 11 participants had their unprovoked seizure relapse while taking antiseizure medication; longer treatment durations were not associated with decreased risk of unprovoked seizure relapse. Following the non-representative online survey, most neuro-intensivists consider 3 months or less of antiseizure medication to be adequate. Even in case of structural etiology, acute symptomatic seizures bear a low risk of subsequent unprovoked seizures. There is still no evidence favoring long-term treatments with antiseizure medications. Hence, individual constellations with an increased risk of unprovoked seizure relapse should be identified, such as central nervous system infections causing structural brain damage. However, in the absence of high-risk features, antiseizure medications should be discontinued early to avoid overtreatment.
Hello, health enthusiasts! Today, we're moving our spotlight from general health and fitness to something more specific but equally important — allergies and intolerances. Ready to unravel these common yet often misunderstood health issues? Let's dive right in! Allergies vs. Intolerances: Two sides of the coin Unraveling the difference: Is it an allergy or an
For treating Acute sinusitis in children both amoxicillin and amoxicillin-clavulanate were equally effective, but amoxicillin-clavulanate had higher rates of gastrointestinal symptoms and yeast...
Applying the systematic approach of medical differential diagnosis to investing helps us recognize financial symptoms, generate investment options, evaluate them objectively, narrow choices, make informed decisions, and adapt to changing market conditions.
Troponins should not be routinely sent in patients presenting with SVT. Rarely, they may be necessary if the patient has concerning ischemic symptoms that persist after conversion to sinus rhythm.
According to a cohort study of 165 patients diagnosed with swimming-induced pulmonary oedema (SIPE), 38 % of patients reported ongoing symptoms after ten days of diagnosis. The research found the most...